A spotlight shines over a theater audience while one woman looks preoccupied

Thinking about your uncomplicated urinary tract infection (uUTI) showing up rather than focusing on the next act?

uUTIs shouldn't run the show. PIVYA provides targeted
action against the most common cause of your uUTI.

About PIVYA

A Targeted Treatment for uUTIs

PIVYA^® (pivmecillinam) tablets is an FDA-approved, penicillin-class antibiotic indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. It's been used in multiple European countries for nearly 50 years and was approved by the FDA for use in the US in 2024.^1-3

You don't have to guess your way through this.

uUTI is one of the most common infections women deal with—and one of the most disruptive to daily life, from sleep to workouts to time with the people you care about. PIVYA is a targeted treatment option, so you can spend less time wondering and more time feeling like yourself again.^2,4

One study found that approximately 50% of women will have one uUTI in their lifetime. Applying that to today's population, that's 15 to 17 million women who have had a uUTI last year alone.^5,6

Woman holding PIVYA (pivmecillinam) 185 mg tablets

Why PIVYA?

Targeted by Design

PIVYA is a targeted-spectrum antibacterial designed to treat the bacteria responsible for most uUTIs while helping preserve the body's normal bacterial flora.^1-3

Proven Efficacy

The efficacy of PIVYA for uUTI was evaluated in controlled clinical trials, including a head-to-head study against a standard antibacterial. Ask your doctor if PIVYA is right for you.²

A Short, Defined Course

PIVYA is taken 3 times a day for as few as 3 days (up to 7 days as clinically indicated)—with no dosage adjustment needed for pregnant women, renal impairment, or hepatic impairment, and it can be taken with or without food.²

Walk into your next uUTI appointment ready.

A few quick questions can help you organize what you want to say—and what to ask—before you talk to your doctor about UTI treatment.

This tool is for informational purposes only. It does not diagnose any condition and is not a substitute for professional medical advice. Always consult your healthcare provider for diagnosis and treatment.

Your Doctor Discussion Guide

Things I'm experiencing

How this has been affecting me

Questions I want to ask my doctor

A treatment option to ask about

PIVYA^® (pivmecillinam) tablets is an FDA-approved, targeted treatment option for uUTIs in adult women 18 and older. Ask your doctor if it's right for you.

PIVYA Savings Program: eligible covered patients may pay as little as $0; eligible not-covered patients may pay as little as $15. RxBIN 637765, RxPCN CRX, RxGroup ALMB1001, ID 12061300201.

Copay Card Terms and Conditions

Patient must be 18 years of age or older.
Patient must have private/commercial insurance—whether the drug is covered on their plan or "Not Covered" (plan doesn't cover it, or has an NDC block, prior authorization, step edit, or other unmet restriction).
Not valid for patients eligible for reimbursement through any federal, state, or other government program (e.g., Medicare, Medicaid, TRICARE).
Reimbursement limits apply; patients with high-deductible or coinsurance plans may pay more than $0. Patient is responsible for all costs after limits are reached.
Questions? Contact the Alembic Copay support line at (312)-395-7386

INDICATION AND IMPORTANT SAFETY INFORMATIONINDICATION AND IMPORTANT SAFETY INFORMATION

PIVYA^® (pivmecillinam) tablets is a penicillin class antibiotic for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible bacteria.

Please consult with your healthcare provider before taking PIVYA.

Contraindications

Serious Hypersensitivity

Allergic reactions, including serious allergic reactions, could occur. If you have experienced serious allergic reactions to PIVYA, penicillins, cephalosporins, carbapenems or other beta-lactam antibacterials you should not take this medication.

Carnitine Deficiency

The medication should not be taken if you have primary or secondary carnitine deficiency, including those with inherited metabolic disorders like methylmalonic aciduria or propionic acidemia.

Acute Porphyria

Patients with porphyria should not use this medication due to the risk of triggering acute attacks. Porphyria is a group of rare, usually genetic disorders caused by enzyme deficiencies in heme production.

Warnings and Precautions

Hypersensitivity and Severe Skin Reactions

Allergic reactions, some serious, could occur with PIVYA and may require immediate treatment. If you have experienced severe allergic reactions to PIVYA, penicillins, cephalosporins, carbapenems or other beta-lactam antibacterials you should inform your healthcare provider. If you develop a new rash, urticaria, drug eruption, swelling of the face, difficulty in breathing or other symptoms of allergic reaction contact your healthcare provider.

Diarrhea

Diarrhea is a common problem caused by antibacterial drugs, including PIVYA. Seek medical attention if you experience watery or bloody stools, with or without stomach cramps and fever while taking PIVYA for two or more months after your last dose.

Antibacterial Resistance

It is common to feel better early in the course of therapy. If this occurs it is important to continue with treatment as directed by your healthcare provider to avoid decreasing the effectiveness of the treatment and increasing the likelihood of developing bacteria that are resistant to the drug.

Pregnancy/Newborns

While observational studies indicate no significant risks, treatment of pregnant patients shortly before delivery may cause a false positive result for isovaleric acidemia in newborn screenings.

Drug Interactions

Other Pivalate-Generating Drugs

Avoid concurrent treatment with valproic acid, valproate, or other pivalate-generating drugs. Please inform your healthcare provider of all medications you're taking and all pre-existing conditions.

Methotrexate

Clearance of methotrexate from the body can be reduced by concurrent use of drugs in the penicillin class, including PIVYA. Please inform your healthcare provider of all medications you're taking and all pre-existing conditions.

Drug Interference with Newborn Screening Test

Treatment of a pregnant individual with PIVYA prior to delivery may cause a false positive test for isovaleric acidemia in the newborn as part of newborn screening.

Common Side Effects (greater than 1%)

Gastrointestinal

Nausea, diarrhea

Genitourinary

Vulvovaginal candidiasis (yeast infection) and genital pruritus (itching).

Other

Headache.

Always consult a healthcare provider for a full evaluation of risks based on medical history.

If you believe you experienced an ADVERSE REACTION from taking PIVYA, please contact Alembic Therapeutics at 1-866-210-9797 or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see full Prescribing Information: pivya.com/assets/pdf/pivya-prescribing-information.pdf.

References

Lodise TP, Kaye KS, Santerre Henriksen A, Kahlmeter G. Review of the in vitro microbiological activity of mecillinam against common uropathogens in uncomplicated urinary tract infection: focus on resistant pathogens. Open Forum Infect Dis. 2024;11(6):ofae296.
PIVYA. Prescribing information. Alembic Therapeutics; 2024.
Data on file.
Thompson J, Marijam A, Mitrani-Gold FS, Wright J, Joshi AV. Activity impairment, health-related quality of life, productivity, and self-reported resource use and associated costs of uncomplicated urinary tract infection among women in the United States. PLoS One. 2023;18(2):e0277728.
Griebling L. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol. 2005;173(4):1288-1294.
US Census Bureau. U.S. and World Population Clock. Accessed September 29, 2024. https://www.census.gov/popclock/.